{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:48:11Z","timestamp":1788601691655,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00467-024-06400-x","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T13:01:41Z","timestamp":1715691701000},"page":"2773-2777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Activin A: a marker of mineral bone disorder in children with chronic kidney disease?"],"prefix":"10.1007","volume":"39","author":[{"given":"Raagul","family":"Shankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0251-2822","authenticated-orcid":false,"given":"Abhijeet","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachita Singh","family":"Dhull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukshana","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"6400_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359","journal-title":"Kidney Int Suppl"},{"key":"6400_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2215\/CJN.02110217","volume":"13","author":"MM Mitsnefes","year":"2018","unstructured":"Mitsnefes MM, Betoko A, Schneider MF et al (2018) FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clin J Am Soc Nephrol 13:45\u201352. https:\/\/doi.org\/10.2215\/CJN.02110217","journal-title":"Clin J Am Soc Nephrol"},{"key":"6400_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00467-012-2324-4","volume":"28","author":"WK Perry","year":"2013","unstructured":"Perry WK (2013) Bone disease in Pediatric Chronic Kidney Disease. Pediatr Nephrol 28:569\u2013576. https:\/\/doi.org\/10.1007\/s00467-012-2324-4","journal-title":"Pediatr Nephrol"},{"key":"6400_CR4","first-page":"391","volume":"21","author":"P Koce\u0142ak","year":"2012","unstructured":"Koce\u0142ak P, Olszanecka-Glinianowicz M, Chudek J (2012) Fibroblast growth factor 23 structure, function and role in kidney diseases. Adv Clin Exp Med 21:391\u2013401","journal-title":"Adv Clin Exp Med"},{"key":"6400_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bone.2017.01.023","volume":"100","author":"KA Hruska","year":"2017","unstructured":"Hruska KA, Sugatani T, Agapova O, Fang Y (2017) The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology. Bone 100:80\u201386. https:\/\/doi.org\/10.1016\/j.bone.2017.01.023","journal-title":"Bone"},{"key":"6400_CR6","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/ijms19092490","volume":"19","author":"T Sugatani","year":"2018","unstructured":"Sugatani T (2018) Systemic activation of activin a signaling causes chronic kidney disease-mineral bone disorder. Int J Mol Sci 19:2490. https:\/\/doi.org\/10.3390\/ijms19092490","journal-title":"Int J Mol Sci"},{"key":"6400_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ndt\/gfaa203","volume":"36","author":"G Cianciolo","year":"2021","unstructured":"Cianciolo G, La Manna G, Capelli I et al (2021) The role of activin: the other side of chronic kidney disease-mineral bone disorder? Nephrol Dial Transplant 36:966\u2013974. https:\/\/doi.org\/10.1093\/ndt\/gfaa203","journal-title":"Nephrol Dial Transplant"},{"key":"6400_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4103\/2230-8210.192914","volume":"20","author":"S Shetty","year":"2016","unstructured":"Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV (2016) Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab 20:846\u2013852. https:\/\/doi.org\/10.4103\/2230-8210.192914","journal-title":"Indian J Endocrinol Metab"},{"key":"6400_CR9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.kint.2016.02.002","volume":"89","author":"OA Agapova","year":"2016","unstructured":"Agapova OA, Fang Y, Sugatani T, Seifert ME, Hruska KA (2016) Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int 89:1231\u20131243. https:\/\/doi.org\/10.1016\/j.kint.2016.02.002","journal-title":"Kidney Int"},{"key":"6400_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5414\/CN109650","volume":"91","author":"F Lima","year":"2016","unstructured":"Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH (2016) Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers. Clin Nephrol 91:222\u2013230. https:\/\/doi.org\/10.5414\/CN109650","journal-title":"Clin Nephrol"},{"key":"6400_CR11","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1093\/ckj\/sfad238","volume":"6","author":"A Nordholm","year":"2023","unstructured":"Nordholm A, S\u00f8rensen IMH, Bjergfelt SS et al (2023) Plasma activin A rises with declining kidney function and is independently associated with mortality in patients with chronic kidney disease. Clin Kidney J 6:2712\u20132720. https:\/\/doi.org\/10.1093\/ckj\/sfad238","journal-title":"Clin Kidney J"},{"key":"6400_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1042\/BSR20190206","volume":"39","author":"H Iriuchishima","year":"2019","unstructured":"Iriuchishima H, Maeshima A, Takahashi S et al (2019) Activin A: a novel urinary biomarker of renal impairment in multiple myeloma. Biosci Rep 39:7. https:\/\/doi.org\/10.1042\/BSR20190206","journal-title":"Biosci Rep"},{"key":"6400_CR13","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1210\/jcem.81.6.8964839","volume":"81","author":"K Harada","year":"1996","unstructured":"Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, Saito S (1996) Serum immunoreactiveactivin A levels in normal subjects and patients with various diseases. J Clin Endocrinol Metab 81:2125\u20132130. https:\/\/doi.org\/10.1210\/jcem.81.6.8964839","journal-title":"J Clin Endocrinol Metab"},{"key":"6400_CR14","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00198-012-2198-0","volume":"24","author":"AD Anastasilakis","year":"2013","unstructured":"Anastasilakis AD, Polyzos SA, Makras P et al (2013) Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment. Osteoporos Int 24:2127\u20132132. https:\/\/doi.org\/10.1007\/s00198-012-2198-0","journal-title":"Osteoporos Int"},{"key":"6400_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1006\/bbrc.1994.2685","volume":"205","author":"S Inoue","year":"1994","unstructured":"Inoue S, Orimo A, Hosoi T et al (1994) Demonstration of activin-A in arteriosclerotic lesions. Biochem Biophys Res Commun 205:441\u2013448. https:\/\/doi.org\/10.1006\/bbrc.1994.2685","journal-title":"Biochem Biophys Res Commun"},{"key":"6400_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/01.asn.0000103225.68136.e6","volume":"15","author":"S Yamashita","year":"2004","unstructured":"Yamashita S, Maeshima A, Kojima I et al (2004) Activin A is a potent activator of renal interstitial fibroblasts. J Am Soc Nephrol 15:91\u2013101. https:\/\/doi.org\/10.1097\/01.asn.0000103225.68136.e6","journal-title":"J Am Soc Nephrol"},{"key":"6400_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ki.2010.107","volume":"78","author":"M van Husen","year":"2010","unstructured":"van Husen M, Fischer A-K, Lehnhardt A et al (2010) Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 78:200\u2013206. https:\/\/doi.org\/10.1038\/ki.2010.107","journal-title":"Kidney Int"},{"key":"6400_CR18","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00467-011-1870-5","volume":"26","author":"E Siomou","year":"2011","unstructured":"Siomou E, Challa A, Printza N et al (2011) Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol 26:1105\u20131114. https:\/\/doi.org\/10.1007\/s00467-011-1870-5","journal-title":"Pediatr Nephrol"},{"key":"6400_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1358\/dnp.2004.17.1.829022","volume":"17","author":"BR Troen","year":"2004","unstructured":"Troen BR (2004) The role of cathepsin K in normal bone resorption. Drug News Perspect 17:19\u201328. https:\/\/doi.org\/10.1358\/dnp.2004.17.1.829022","journal-title":"Drug News Perspect"},{"key":"6400_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.lab.2005.03.016","volume":"146","author":"G Holzer","year":"2005","unstructured":"Holzer G, Noske H, Lang T, Holzer L, Willinger U (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146:13\u201317. https:\/\/doi.org\/10.1016\/j.lab.2005.03.016","journal-title":"J Lab Clin Med"},{"key":"6400_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.maturitas.2011.11.024","volume":"71","author":"D Adolf","year":"2012","unstructured":"Adolf D, Wex T, Jahn O et al (2012) Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women. Maturitas 71:169\u2013172. https:\/\/doi.org\/10.1016\/j.maturitas.2011.11.024","journal-title":"Maturitas"},{"key":"6400_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.maturitas.2013.01.005","volume":"74","author":"S Piatek","year":"2013","unstructured":"Piatek S, Adolf D, Wex T et al (2013) Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor \u03baB ligand in the diagnosis of osteoporosis. Maturitas 74:363\u2013368. https:\/\/doi.org\/10.1016\/j.maturitas.2013.01.005","journal-title":"Maturitas"},{"key":"6400_CR23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.exger.2005.04.001","volume":"40","author":"K Kerschan-Schindl","year":"2005","unstructured":"Kerschan-Schindl K, Hawa G, Kudlacek S, Woloszczuk W, Pietschmann P (2005) Serum levels of cathepsin K decrease with age in both women and men. Exp Gerontol 40:532\u2013535. https:\/\/doi.org\/10.1016\/j.exger.2005.04.001","journal-title":"Exp Gerontol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06400-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:08:37Z","timestamp":1721884117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06400-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["6400"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06400-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they do not have any conflict of interest associated with the research work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}